These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23755745)

  • 1. Is there a role for agomelatine in the treatment of anxiety disorders?A review of published data.
    De Berardis D; Conti CM; Marini S; Ferri F; Iasevoli F; Valchera A; Fornaro M; Cavuto M; Srinivasan V; Perna G; Carano A; Piersanti M; Martinotti G; Di Giannantonio M
    Int J Immunopathol Pharmacol; 2013; 26(2):299-304. PubMed ID: 23755745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of duloxetine in the treatment of anxiety disorders.
    De Berardis D; Serroni N; Carano A; Scali M; Valchera A; Campanella D; D'Albenzio A; Di Giuseppe B; Moschetta FS; Salerno RM; Ferro FM
    Neuropsychiatr Dis Treat; 2008 Oct; 4(5):929-35. PubMed ID: 19183783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agomelatine for the treatment of generalized anxiety disorder.
    Buoli M; Grassi S; Serati M; Altamura AC
    Expert Opin Pharmacother; 2017 Sep; 18(13):1373-1379. PubMed ID: 28730851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of preliminary observations on agomelatine in the treatment of anxiety disorders.
    Levitan MN; Papelbaum M; Nardi AE
    Exp Clin Psychopharmacol; 2012 Dec; 20(6):504-9. PubMed ID: 23088208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agomelatine in treating generalized anxiety disorder.
    Demyttenaere K
    Expert Opin Investig Drugs; 2014 Jun; 23(6):857-64. PubMed ID: 24766542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.
    Stein DJ; Ahokas AA; de Bodinat C
    J Clin Psychopharmacol; 2008 Oct; 28(5):561-6. PubMed ID: 18794654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.
    Stein DJ; Khoo JP; Ahokas A; Jarema M; Van Ameringen M; Vavrusova L; Hӧschl C; Bauer M; Bitter I; Mosolov SN; Olivier V; Matharan S; Picarel-Blanchot F; de Bodinat C
    Eur Neuropsychopharmacol; 2018 Aug; 28(8):970-979. PubMed ID: 30135032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in Pharmacotherapy for Pediatric Anxiety Disorders.
    Nicotra CM; Strawn JR
    Child Adolesc Psychiatr Clin N Am; 2023 Jul; 32(3):573-587. PubMed ID: 37201968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trajectory and magnitude of response in adults with anxiety disorders: a Bayesian hierarchical modeling meta-analysis of selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and benzodiazepines.
    Mendez EM; Mills JA; Suresh V; Stimpfl JN; Strawn JR
    CNS Spectr; 2024 Jun; 29(3):187-196. PubMed ID: 38523533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
    Kasper S; Hamon M
    World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study.
    Stein DJ; Ahokas A; Márquez MS; Höschl C; Oh KS; Jarema M; Avedisova AS; Albarran C; Olivier V
    J Clin Psychiatry; 2014 Apr; 75(4):362-8. PubMed ID: 24569045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study.
    Stein DJ; Ahokas A; Albarran C; Olivier V; Allgulander C
    J Clin Psychiatry; 2012 Jul; 73(7):1002-8. PubMed ID: 22901350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The preclinical discovery and development of agomelatine for the treatment of depression.
    Konstantakopoulos G; Dimitrakopoulos S; Michalopoulou PG
    Expert Opin Drug Discov; 2020 Oct; 15(10):1121-1132. PubMed ID: 32568567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and Novel Psychopharmacological Drugs for Anxiety Disorders.
    Bandelow B
    Adv Exp Med Biol; 2020; 1191():347-365. PubMed ID: 32002937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence of agomelatine's antidepressant efficacy: the key points.
    Eser D; Baghai TC; Möller HJ
    Int Clin Psychopharmacol; 2007 Oct; 22 Suppl 2():S15-9. PubMed ID: 17917562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacologic treatment of anxiety disorders: a review of progress.
    Ravindran LN; Stein MB
    J Clin Psychiatry; 2010 Jul; 71(7):839-54. PubMed ID: 20667290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review.
    Gomez AF; Barthel AL; Hofmann SG
    Expert Opin Pharmacother; 2018 Jun; 19(8):883-894. PubMed ID: 29806492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological treatment for generalized anxiety disorder in adults: an update.
    Reinhold JA; Rickels K
    Expert Opin Pharmacother; 2015; 16(11):1669-81. PubMed ID: 26159446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study.
    Stein DJ; Ahokas A; Jarema M; Avedisova AS; Vavrusova L; Chaban O; Gruget C; Olivier V; Picarel-Blanchot F; de Bodinat C
    Eur Neuropsychopharmacol; 2017 May; 27(5):526-537. PubMed ID: 28298261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Agomelatine in the treatment of major depressive disorder: assessment of the efficacy and tolerability].
    Filippova NV; Barylnik YB; Shuldyakov AA; Antonova AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(5):154-161. PubMed ID: 31317905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.